Pralatrexate is an antifolate with high affinity for the reduced folate carrier 1 (RFC-1) protein and folylpolyglutamate synthetase (FPGS), resulting in extensive internalization and accumulation within tumour cells. Here, RFC1 is linked to neoplasm.